Sermorelin compounding pharmacies: Empower, Olympia, and quality checks

What Empower publishes

Empower's sermorelin acetate ODT page lists an orally disintegrating tablet and provides a product reference. Its formulation announcement describes the ODT alongside an injectable option and directs patients toward a prescribing provider.

This establishes that the pharmacy markets different formats. It does not prove that the tablet and injection produce equivalent clinical outcomes. The product reference discusses research involving different populations and, in places, other hormone treatments. Ask how each citation applies to the exact preparation proposed.

Our tablet and troche guide explains why dissolution, absorption, and clinical benefit are separate questions. A pharmacy's product page should not be treated as a personalized diagnosis or dose instruction.

What Olympia publishes

Olympia's peptide catalog lists a sermorelin acetate injection and an NAD+ and sermorelin bundle. Its fitness article describes intended uses and practical considerations from the provider's perspective.

Those pages are evidence of catalog offerings and marketing. They do not establish a universal cash price, confirm that a specific clinic orders from Olympia, or prove that a combination improves outcomes. Concentrations and formulations should be read from the current dispensing label rather than an old catalog or blog.

If a program says it uses Olympia, ask for the exact dispensing entity, formulation, quantity, and pharmacy contact. The brand relationship may vary by product or location.

503A and 503B are not quality scores

The FDA's compounding overview explains the distinction between traditional compounding and registered outsourcing facilities, including the different regulatory conditions involved. A business can describe more than one operation, so a corporate name does not settle the status of the facility preparing your medicine.

Neither “503A” nor “503B” means that a compounded product is FDA-approved for safety, effectiveness, and quality. Ask which operation is involved in your preparation. Avoid treating a facility category as an independent clinical endorsement.

What a quality claim should let you check

Ask about the pharmacy license, contact information, active ingredients, concentration, lot identification, storage instructions, and beyond-use date. If a provider advertises testing, ask which tests apply to the finished preparation and whether the information corresponds to its lot.

A purity result is not automatically a sterility result. A sterility claim does not establish clinical benefit. The FDA's compounded-drug risk resource explains why contamination and incorrect strength matter, while the state-board resource helps verify licensing.

We have not independently audited these pharmacies or tested dispensed products. Public information can identify questions to ask, but it should not be described as independent verification of every lot.

Check the package when it arrives

Make sure the label is readable and consistent with the prescription. If the concentration or appearance differs from a previous fill, ask before using it. Keep the packaging details available if there is a shipping or temperature concern.

The storage and travel guide explains why a pharmacy-specific beyond-use date and excursion assessment matter. Do not infer a shelf life from another product or from how cold the package feels.

Know which team handles which problem

Prescription changes belong with the prescriber, product preparation and label questions with the pharmacist, and subscription charges with the program's billing team. Ask how those teams coordinate if an issue crosses roles.

Our buying guide brings these checks together. A dependable process makes it easy to identify the responsible professional rather than leaving a patient to guess which logo on the package matters.